These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17671159)

  • 1. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
    Sangha R; Butts C
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
    J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers.
    North S; Butts C
    Expert Rev Vaccines; 2005 Jun; 4(3):249-57. PubMed ID: 16026241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.
    Butts C; Murray RN; Smith CJ; Ellis PM; Jasas K; Maksymiuk A; Goss G; Ely G; Beier F; Soulières D
    Clin Lung Cancer; 2010 Nov; 11(6):391-5. PubMed ID: 21071331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer.
    Sangha R; North S
    Expert Opin Biol Ther; 2007 Nov; 7(11):1723-30. PubMed ID: 17961094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer.
    Powell E; Chow LQ
    Expert Rev Respir Med; 2008 Feb; 2(1):37-45. PubMed ID: 20477220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
    Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
    Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emepepimut-S for non-small cell lung cancer.
    Corrales-Rodriguez L; Blais N; Soulières D
    Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
    Mehta NR; Wurz GT; Burich RA; Greenberg BE; Griffey S; Gutierrez A; Bell KE; McCall JL; Wolf M; DeGregorio M
    Clin Cancer Res; 2012 May; 18(10):2861-71. PubMed ID: 22434666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.
    Butts C; Maksymiuk A; Goss G; Soulières D; Marshall E; Cormier Y; Ellis PM; Price A; Sawhney R; Beier F; Falk M; Murray N
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1337-42. PubMed ID: 21744082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer.
    Neninger Vinageras E; de la Torre A; Osorio Rodríguez M; Catalá Ferrer M; Bravo I; Mendoza del Pino M; Abreu Abreu D; Acosta Brooks S; Rives R; del Castillo Carrillo C; González Dueñas M; Viada C; García Verdecia B; Crombet Ramos T; González Marinello G; Lage Dávila A
    J Clin Oncol; 2008 Mar; 26(9):1452-8. PubMed ID: 18349395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.
    Wu YL; Park K; Soo RA; Sun Y; Tyroller K; Wages D; Ely G; Yang JC; Mok T
    BMC Cancer; 2011 Oct; 11():430. PubMed ID: 21982342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
    Barve M; Bender J; Senzer N; Cunningham C; Greco FA; McCune D; Steis R; Khong H; Richards D; Stephenson J; Ganesa P; Nemunaitis J; Ishioka G; Pappen B; Nemunaitis M; Morse M; Mills B; Maples PB; Sherman J; Nemunaitis JJ
    J Clin Oncol; 2008 Sep; 26(27):4418-25. PubMed ID: 18802154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
    Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
    BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.